Comparative Pharmacology
Head-to-head clinical analysis: FLUOROURACIL versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROURACIL versus SIKLOS.
FLUOROURACIL vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is metabolized to active nucleotides (FdUMP, FUTP) which incorporate into RNA and inhibit thymidylate synthase, leading to cell cycle arrest and apoptosis.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
425 mg/m² IV bolus on days 1-5 every 28 days (Mayo regimen) or 400 mg/m² IV bolus on day 1, then 2400 mg/m² continuous IV infusion over 46 hours (FOLFOX regimen). For topical use, 5% cream applied twice daily for 2-4 weeks.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateFluorouracil + Digoxin
"Fluorouracil may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFluorouracil + Digitoxin
"Fluorouracil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFluorouracil + Deslanoside
"Fluorouracil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFluorouracil + Acetyldigitoxin
"Fluorouracil may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial α-phase 10-20 min; terminal β-phase 16-20 min (no accumulation). For continuous infusion, functional half-life ~20 min. Clinically, rapid clearance necessitates infusion schedules.
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Renal: 60-80% as intact drug and metabolites (primarily urea, CO2, α-fluoro-β-alanine). Fecal: <10%. Biliary: minor.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category D/X
Category C
Antimetabolite
Antimetabolite